Explore 3 Stock Ideas & Industry Insights Download Free Report

Announcements

US 12 Month Natural Gas Fund NAV Falls to $5.71 in Q3 2026

United States 12 Month Natural Gas Fund, LP (NYSE Arca:UNL) filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 9, 2026, reporting a net asset value per share of $5.71 and total partners' capital of $15,985,679.

Aakashdeep | 09 November 2026

Berkshire Hathaway Q3 2026: $22.1B Net Earnings Reported

Berkshire Hathaway Inc. filed its Form 10-Q with the SEC on November 9, 2026, covering the quarterly period ended September 30, 2026, reporting consolidated financial results for the third quarter and first nine months of 2026.

Shwetambri Chauhan | 09 November 2026

Sohu Q3 2026: Revenue Falls 26%, Net Loss $15M

Sohu.com Limited (NASDAQ:SOHU) reported unaudited financial results for the third quarter ended September 30, 2026, disclosing a 26% year-over-year decline in total revenues and a GAAP net loss attributable to the company of US$15 million.

Anjali Anand | 08 November 2026

FFR OmniMind Ranks No. 1 on RoboColiseum Leaderboard

FF EAI Robotics Ecosystem Inc. filed an 8-K on November 8, 2026, sharing a weekly business update from Founder and Global CEO YT Jia that highlighted OmniMind's top ranking on RoboColiseum's global leaderboard as of November 6, 2026.

Anjali Anand | 08 November 2026

Cars.com Grants 373,345 RSUs to New CPO Mausam Bhatt

Cars.com Inc. filed an 8-K on November 8, 2026, disclosing that its Compensation Committee granted 373,345 restricted stock units to Mausam Bhatt as an inducement to his employment as Chief Product Officer, effective November 2, 2026.

Shwetambri Chauhan | 08 November 2026

Johnson & Johnson Phase 1 Data: Pasritamig Plus JNJ-9401

Johnson & Johnson (NYSE:JNJ) disclosed Phase 1 clinical results for the investigational combination of pasritamig and JNJ-9401 in metastatic castration-resistant prostate cancer, presented at the Society for Immunotherapy of Cancer 2026 Annual Meeting on November 8, 2026.

Shwetambri Chauhan | 08 November 2026

Johnson & Johnson Shares Nipocalimab SjD Patient Data at ACR 2026

Johnson & Johnson issued a press release on November 7, 2026, announcing new patient experience findings from the Phase 2 DAHLIAS study of nipocalimab in Sjogren's disease, to be presented at the American College of Rheumatology Convergence 2026.

Anjali Anand | 07 November 2026

J&J ICOTYDE Phase 3 PsA Study: 58% ACR20 at Week 16

Johnson & Johnson announced positive Phase 3 results for ICOTYDE (icotrokinra) in biologic-naive adults with active psoriatic arthritis, presented as a late-breaking poster at the American College of Rheumatology Convergence 2026 on November 7, 2026.

Manish Choudhary | 07 November 2026

SharkNinja CEO Barrocas Sells 113,156 Shares on Nov. 6

Mark Barrocas, Chief Executive Officer and Director of SharkNinja, Inc., filed a Form 4 on November 6, 2026, disclosing the sale of 113,156 ordinary shares across seven transactions on that same date.

Manish Choudhary | 06 November 2026

Garmin VP Maxfield Gifts 5 Shares to Charity Nov 2026

Joshua H. Maxfield, VP and General Counsel of Garmin Ltd, filed a Form 4 on November 6, 2026, disclosing a disposition of 5 registered shares gifted to a charitable organization on November 5, 2026.

Shwetambri Chauhan | 06 November 2026
Support

Hi! How can we help you today?

Loading…